// App-Quantinova.ai

5516 : Combination of PARP and ATR inhibitors (olaparib and ceralasertib) shows clinical activity in acquired PARP inhibitor-resistant recurrent ovarian cancer.

Researchers

Presenter

  • Stephanie L. Wethington

Principal Investigators

  • Payal D Shah

  • Lainie P. Martin

  • Janos Laszlo Tanyi

  • Nawar A. Latif

  • Mark Aloysuis Morgan

  • Drew A. Torigian

  • Cheyenne Pagan

  • Diego Rodriguez

  • Susan M. Domchek

  • Ronny Drapkin

  • Ie-Ming Shih

  • Simon Smith

  • Emma Dean

  • Deborah Kay Armstrong

  • Stephanie Gaillard

  • Fiona Simpkins

Medical Centers

  • Johns Hopkins University, Baltimore, MD

  • University of Pennsylvania, Philadelphia, PA

  • University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA

  • University of Pennsylvania Perelman School of Medicine, Philadelphia, PA

  • Hospital of the University of Pennsylvania, Philadelphia, PA

  • Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA

  • Dana-Farber Cancer Institute, Boston, MA

  • University of Manchester and The Christie NHS FT, Manchester, United Kingdom

  • The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD

  • Johns Hopkins University School of Medicine, Baltimore, MD

  • University of Pennsylvania Perelman School of Medicine, Philadelphia, PA

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Genetic Disorder

Disease

  • Gynaecological cancer

  • High grade serous ovarian cancer

Biomarkers

  • Ataxia Telangiectasia And Rad3-Related Protein

  • Cancer antigen 125

  • Breast cancer type 1 susceptibility protein

Drug/Treatment

  • Olaparib

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • N/A

Study Id's

  • NCT03462342

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved